A Game-Changing Collaboration
In a groundbreaking partnership that holds the promise of revolutionizing the treatment of deep-seated tumors, Leo Cancer Care and THERYQ, based in PEYNIER, France, have combined their extensive expertise. This collaboration, driven by cutting-edge technology and precision engineering, seeks to elevate the confidence and precision of cancer treatment for radiation oncologists and patients alike.
At its core, this partnership introduces FLASH radiotherapy, an advanced radiation therapy technique that delivers extraordinarily high radiation doses within a fraction of a second. This breakthrough approach significantly reduces treatment duration and minimizes damage to surrounding healthy tissues, potentially ushering in a new era in cancer care.
The Evolution of FLASH Radiotherapy
Developed in collaboration with CHUV (Lausanne University Hospital, Switzerland) and grounded in CERN technology (European Laboratory of Particle Physics), FLASHDEEP represents a monumental leap forward in cancer radiotherapy. This groundbreaking innovation offers ultra-rapid treatment delivery with minimal impact on healthy surrounding tissues.
By effectively addressing the unique challenge of precisely targeting deep-seated tumors, this collaborative effort aims to maximize the therapeutic potential of Very High-Energy Electron (VHEE) FLASH radiotherapy. Notably, the first unit to feature Leo Cancer Care’s novel upright patient positioning solution will be installed at CHUV, paving the way for transformative advancements.
Key Advantages of the Collaboration
In this pioneering collaboration, several key highlights are poised to redefine the landscape of cancer treatment:
- Improved Patient Comfort: Innovative upright patient positioning minimizes discomfort during cancer therapy, enhancing the overall patient experience.
- Enhanced Treatment Precision: The integration of Leo Cancer Care and THERYQ’s cutting-edge technology enables precise targeting of deep-seated tumors, thereby minimizing harm to surrounding healthy tissues.
- Faster Treatment: FLASHDEEP’s ultra-fast delivery system optimizes setup times and enhances overall treatment efficiency.
- Improved Clinical Outcomes: By addressing the complexities of deep tumor treatment, this collaboration holds the potential to enhance patient outcomes, particularly in challenging cancer diagnoses.
A Shared Vision of Transformation
Both Leo Cancer Care and THERYQ share a relentless commitment to pushing the boundaries of cancer care. This collaboration represents a significant milestone in their joint mission to redefine radiation therapy. Teams at both organizations are enthusiastic about embarking on this journey together, with plans to share further project details in the months ahead.
Stephen Towe, CEO and co-founder of Leo Cancer Care, comments,
“FLASH has been one of the most exciting research areas within radiation therapy for a number of years now, so we are very excited to be partnering with THERYQ, helping them to bring FLASH radiotherapy into mainstream clinical practice.”
Ludovic Le Meunier, CEO of THERYQ said,
“Together, we are pioneering the future of cancer treatment, where precision meets speed, and patients receive the best care possible. This collaboration reaffirms our commitment to advancing FLASH radiation therapy systems, bringing hope and healing to those in need,”
THERYQ: Revolutionizing Cancer Care
THERYQ is a trailblazing medical device company specializing in the design, manufacturing, and commercialization of FLASH radiotherapy systems. With a clear mission in mind, their goal is to expand the application of radiotherapy in oncology and unlock new avenues of treatment for cancer patients.
THERYQ aims to enhance patient care, improve life expectancies, and elevate the overall quality of life by providing efficient, precise, and ultra-short radiation treatments.
Leo Cancer Care: Transforming Radiation Therapy
Leo Cancer Care is on a mission to challenge the norms in radiation therapy, with a focus on delivering improved patient care and an enhanced patient experience.
Their products are rooted in the clinical benefits of upright patient positioning, coupled with a shift from machine rotation to patient rotation.